Teva CEO Steps Down While An Integration Hangs In The Balance
Executive Summary
After a damaging court ruling on Copaxone 40 mg and some management missteps, CEO Erez Vigodman will step down as CEO of the Israeli generic drug leader. Chairman Yitzhak Peterburg will fill in on an interim basis.
You may also be interested in...
Teva SOS: Troubled Drug Maker Seeks Audacious Captain To Take The Wheel
Teva investors have moved beyond restless to the point of jumping ship as the company's generic drug business continues to underperform, with little guidance on plans for a turnaround.
Teva SOS: Troubled Drug Maker Seeks Audacious Captain To Take The Wheel
Teva investors have moved beyond restless to the point of jumping ship as the company's generic drug business continues to underperform, with little guidance on plans for a turnaround.
2Q Pharma Results Preview: Pfizer, Allergan, Teva, Merck KGaA & Shire
Pfizer will anchor the final week of major biopharma earnings calls, facing the same question as every firm with massive stockpiles of cash: When are you going to spend that money on a transformative M&A deal?